Fundamental Data for ACAD

ACADIA PHA(NSDQ:ACAD)

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinsons disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

# Employees: 63

Address: 3911 Sorrento Valley Boulevard,San Diego,CA,USA

Phone: 858 558-2871

Fax: 858 558-2872

Website: www.acadia-pharm.com

Email: ir@acadia-pharm.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Leslie Iversen (Chmn.)

Michael Borer (Dir.)

Uli Hacksell (C.E.O.; Dir.)

Thomas H. Aasen (C.F.O.; Chief Acctg. Off.)

Gordon Binder (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/8/2010

Mean EPS (Next Qtr): ($0.19)

Mean EPS (Year): ($1.17)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 4

Shares Performance

Period	ACAD	Compare to S&P
YTD	47.78 %	22.30 %
4 Weeks	-16.88 %	-17.77 %
12 Weeks	-77.76 %	-79.03 %

Shares Information

Analyst Coverage: Y

Avg Volume: 493955

Shares Outstanding: 37M

Market Cap: $0.05B

52 Week High: $6.23

52 Week Low: $0.77

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 ACAD split by factor of 0.200

Earnings Performance

EPS Growth in Last Quarter: 32.35 %

EPS Growth in Last Year: 36.11 %

Sales Growth in Last Quarter: 33.79 %

Sales Growth in Last Quarter: 763.48 %

Financials

Qtr Book Value: $1.87

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 10.020